| Literature DB >> 15297072 |
Karen S Slobod1, Jerry L Shenep, Jorge Luján-Zilbermann, Kim Allison, Brita Brown, Ruth Ann Scroggs, Allen Portner, Chris Coleclough, Julia L Hurwitz.
Abstract
Human parainfluenza virus-type 1 (hPIV-1) is the most common cause of pediatric laryngotracheobronchitis (croup) and results in close to 30,000 US hospitalizations each year. No effective vaccine is available. We examined murine PIV-1 (Sendai virus, SeV) as a live, xenotropic vaccine for the closely related human PIV-1 in a phase I, dose escalation study in healthy adults. Intranasal Sendai virus was uniformly well-tolerated and showed evidence of immunogenicity in three of nine vaccinees despite pre-existing, cross-reactive immunity presumably induced by previous exposure to human PIV-1. Results encourage future trials to evaluate the efficacy of Sendai virus in preventing human PIV-1 infection in infants and children.Entities:
Mesh：
Substances：
Year: 2004 PMID： 15297072 DOI： 10.1016/j.vaccine.2004.01.053
Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641